Phase III Study in Refractory Behcet's Disease
Condition: Behcet Disease
MeSH terms: Behcet Syndrome
Intervention: AIN457; AIN457; Placebo
Intervention MeSH terms: Antibodies, Monoclonal
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Enrollment: 118.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Behçet's disease,; intermediate uveitis; panuveitis; posterior uveitis; uveitis

Summary:

      The purpose of this pivotal trial is to evaluate subcutaneous (SQ) AIN457 as an adjunctive
      therapy to reduce the rate of exacerbations of posterior uveitis or panuveitis secondary to
      Behçet's disease during the 24 weeks of study therapy as compared to standard of care alone.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Patients with Behçet's disease and with a history of recurrent uveitis in a least one
             eye.

          -  Documented evidence of >2 recurrent exacerbations of either intermediate uveitis,
             posterior uveitis or panuveitis in the study eye within the past 6 months (this could
             include the current exacerbation for patients having an acute exacerbation at
             screening). Exacerbations fulfilling the study inclusion criteria must have one or
             more of the following recorded in the patients patients medical record for each
             recurrent exacerbation:

               -  >2+ vitreous haze with <2+ anterior chamber cell grade (intermediate or posterior
                  uveitis) or >2+ vitreous haze with >2+ anterior chamber cell grade (panuveitis)

               -  presence of retinal infiltrates or vasculitis or hemorrhages

               -  documented >10 ETDRS letter or 2 line Snellen decrease in visual acuity
                  attributed to ocular inflammation secondary to the recurrent exacerbation of
                  Behçet's disease.

          -  Requirement for either of the following immunosuppressive therapies for at least 3 of
             the past 6 months for the treatment of or to prevent an exacerbation of ocular
             inflammation related to Behçet's disease:

               -  Prednisone or equivalent >10 mg daily

               -  The need for at least >1 periocular injection or >1 intravitreal corticosteroid
                  injection in the study eye within the past 6 months (the last injection must have
                  not been given within 6 weeks of screening)

               -  Treatment with cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil,
                  mycophenolic acid or methotrexate either as monotherapy or in combination with or
                  without steroids. (Patients treated at any time with chlorambucil or
                  cyclophosphamide are not eligible for the study.)

          -  Patients not meeting the above specified criteria for immunomodulatory therapies are
             eligible for enrollment if they are intolerant to systemic immunomodulatory therapy as
             determined by the study investigator.

        Exclusion Criteria:

          -  Subjects with infectious uveitis, uveitis due to other causes than Behçet's disease,
             or uveitis of unknown etiology.

          -  Less severe (i.e. anterior) uveitis associated with Behçet's disease.

        Ocular treatments

          -  Treatment with intravitreal anti-VEGF agents administered to the study eye within 3
             months prior to study screening.

          -  Treatment with any injected or implantable corticosteroid releasing device (i.e.,
             flucinolone acetonide implant, Retisert®) in the study eye within the last 3 years.

          -  Intraocular surgery or laser photocoagulation in the study eye within the last 6 weeks
             prior to screening except for a diagnostic vitreous or aqueous tap with a small-gauge
             needle.

        Systemic conditions or treatments

          -  Treatment with any live or live-attenuated vaccine (including vaccine for
             varicella-zoster virus or measles) within 2 months prior to screening.

          -  Any systemic biologic therapy (e.g. interferon, infliximab, daclizumab, etanercept, or
             adalimumab) given intravenously or subcutaneously within 3 months prior to screening
             and no prior treatment with AIN457.

          -  Any prior treatment with systemic alkylating agents (cyclophosphamide, chlorambucil).

        Other protocol-defined inclusion/exclusion criteria may apply